Floatz logo

Vinorelbine

BRCA2 Mutation Carrier

The University of Texas Health Science Center at San AntonioPhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the BRCA2 Mutation Carrier cohort.

Asset / SponsorPhaseRating
Veliparib
The University of Texas Health Science Center at San Antonio
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
The University of Texas Health Science Center at San Antonio
Phase 2BB
Cediranib
M.D. Anderson Cancer Center
Phase 2B
Metformin
Alliance for Clinical Trials in Oncology
Phase 3B
Telapristone Acetate
Northwestern University
Phase 2B

View all 9 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →